RIGImmune Inc

RIGImmune is a platform biopharmaceutical company developing innovative RNA therapeutics delivered directly to the respiratory tract, without lipid nanoparticle systems, to improve the lives of patients who suffer from respiratory diseases with high unmet medical need. Led by biopharma industry veteran, President Susan Sobolov, PhD, RIGImmune scientists have discovered and developed a non-LNP nano-emulsion respiratory delivery platform technology named NEEDTM. RIGImmune was launched in 2020 by Yale Professors Anna Marie Pyle, PhD and Akiko Iwasaki, PhD. Pyle and colleagues co-discovered RIG-I, an innate immune sensor, and a new class of oligonucleotide compounds called stem loop RNA therapeutics or SLRs for the selective targeting of RIG-I. Upon sensing viral RNA or tumor DNA, RIG-I stimulates the innate and adaptive immune responses by activation of the Type I interferon pathway. Iwasaki is renowned for her work with mechanisms of immune defense against viruses at the mucosal su...